In order to further explore the challenges faced by the prevention and control of fungal infections in mainland China and improve the diagnosis and treatment pattern of invasive fungal infections, the "Life is More Than Survival" Invasive Fungal Infection Diagnosis and Treatment Summit Forum and The Listing Conference of Kangxinbo were held in 11 cities including Chongqing, Wuhan, Xi'an and Shenzhen on April 23. Professor Huang Xiaojun of Peking University People's Hospital, Professor Ma Jun of Harbin Institute of Hematology and Oncology, Professor Guan Xiangdong of the First Affiliated Hospital of Sun Yat-sen University, Professor Wang Minggui of Huashan Hospital Affiliated to Fudan University, and Professor Xu Yingchun of Peking Union Medical College Hospital delivered speeches with the theme of "Shining the Future, Healing new life together". In addition, authoritative experts from multidisciplinary fields such as blood, infection, respiration, severe disease, and microbiology attended the conference to talk about the current situation, disease burden and new treatment options of invasive mycosis in mainland China.
Pay attention to people at high risk of mold incidence
Improve the quality of treatment
Mucormycetes and Aspergillus are commonly known clinically invasive fungi that can cause infectious diseases in humans, causing invasive mucormycosis and invasive aspergillosis, also known as invasive mycosis. In recent years, with the increase in the number of malignant tumors and the large number of transplant surgeries, the number of immunocompromised people has increased, and the incidence of invasive mycosis has increased. Allogeneic hematopoietic stem cell transplant patients, solid organ transplant patients, critically ill patients in the department of critical care medicine, tumor radiotherapy and chemotherapy patients, and advanced age and long-term chronic diseases and other immunocompromised patients are at high risk of invasive mycosis.
Professor Ma Jun of the Harbin Institute of Hematology and Oncology said that in the field of blood, invasive fungal infections are mostly manifested as invasive aspergillosis and candidiasis, but the incidence of invasive mucormycosis has increased in recent years. The prognosis of these diseases is poor and seriously threatens the lives of patients. Invasive aspergillosis and mucormycosis are difficult to distinguish in their early manifestations. In recent years, the mainland has faced many challenges in the field of clinical treatment of invasive mycosis, mainly reflected in the problems of treatment tolerance, drug interaction, long-term treatment compliance, and the need to monitor drug concentrations.
Professor Huang Xiaojun of Peking University People's Hospital pointed out: "In the future, the field of clinical diagnosis and treatment should solve various complex problems currently facing, such as taking into account the efficacy and safety of mold infection treatment, not only to save patients' lives, but also to reduce additional damage, improve patients' medication experience, and increase doctors' confidence in treatment." In the past ten years, there have been very few innovative drugs, and more generic drugs or new dosage forms have been listed. The listing of Kang Xinbo provides more choices for clinicians, and hopes that more excellent antibacterial drugs will be listed in China in the future to benefit patients.
Strengthen multidisciplinary linkage
Contribute to the rational use of antimicrobials
The diagnosis and treatment of bacterial and fungal infections requires the joint cooperation of clinicians such as infectious diseases, respiratory medicine, intensive care medicine, and hematology, as well as microbiology, clinical pharmacy, hospital sense and other departments, and through multidisciplinary expert exchanges and cooperation, it will help promote the improvement of standardized diagnosis and treatment of infectious st. and sexually transmitted diseases and the improvement of diagnosis and treatment level.
"Infection prevention and control is a very important management link in the field of severe disease, and once a severe patient has a bacterial or fungal infection, the mortality rate will increase significantly." Professor Guan Xiangdong of the First Affiliated Hospital of Sun Yat-sen University said, "The basic diseases of severe patients are complex, and the diagnosis and treatment of infections needs to include infectious diseases, respiratory medicine, hematology, clinical microbiology, clinical pharmacy, and other departments to work together to strengthen the management of fungal infections. ”
Professor Wang Minggui of Huashan Hospital of Fudan University pointed out that China's anti-infection field has undergone great changes in the past few decades, infectious diseases such as hepatitis have a downward trend, and drug-resistant bacterial and fungal infections have become important problems. More and more hospitals have newly established infectious disease departments, focusing on bacterial and fungal infections and fever to be examined. Effective antimicrobials are an important line of defense to protect the lives of infected patients. For refractory infections such as invasive Aspergillus and Mucormycetes, only by strengthening multidisciplinary cooperation in the field of antifungals in China and jointly promoting the development of china's antifungal field can we bring more cures to patients.
Professor Xu Yingchun of the Department of Laboratory Medicine of Peking Union Medical College Hospital said: "In recent years, the proportion of fungal infections in the clinic has increased year by year, and the timely diagnosis results of fungal pathogens are directly related to the best treatment time. Fungal infection, diagnosis first. We need to strengthen the construction of clinical microbiology laboratories, strengthen the cooperation and dialogue between clinicians and microbiology laboratories, and promote the early, rapid and accurate diagnosis of invasive mycosis. It is believed that with the joint efforts of everyone, the level of mycosis monitoring and diagnosis and treatment in mainland China will surely step onto a new level, so that more patients can get scientific and standardized anti-infection management. ”
Peng Zhenke, President of Pfizer Biopharmaceutical Group China, said: "As a company that has been deeply involved in the field of anti-infection for many years, Pfizer aims to 'bring breakthrough innovations that change the lives of patients' and is committed to solving the unmet medical needs in the field of infection. We believe that the listing of Kangxinbo in China will provide innovative treatment options for adult patients with invasive aspergillosis and invasive mucormycosis, helping clinicians to proactively address this type of disease threat." In the future, Pfizer will introduce more innovative drugs to China to benefit more patients. ”
As a broad-spectrum new triazole antifungal drug, Kang Xinbo (Isaconazole sulfate capsule) was approved in December last year and January this year as two indications for adult invasive mucormycosis and invasive aspergillosis, becoming the only oral antifungal drug in mainland China that has been approved for the treatment of invasive mucormycosis and aspergillosis in adult patients at the same time. It is reported that Kang Xinbo is expected to be listed in Beijing, Shanghai, Guangzhou, Nanjing and other cities in The mainland in May this year.